Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is a commercial-stage medical device company that develops and sells the iLet Bionic Pancreas, the first FDA-cleared closed-loop insulin delivery device on the market. The company's strong Q1 results, increased guidance, and expansion of its sales force indicate a positive outlook for its financial performance and future market share in the diabetes sector. Despite a recent FDA Warning Letter, the company remains confident in its ability to continue operations and bring its innovative products to market. This, coupled with a promising innovation pipeline, suggests a strong potential for growth and makes BBNX a top choice for investors looking for a fast-growing MedTech company.

Bears say

Beta Bionics is seen as a high-risk investment due to slower revenue growth compared to its SMID growth peers and a recent decline in NPS momentum. This has resulted in multiple compression and a decrease in the stock price. The company's future prospects remain unclear, with potential overhangs related to management execution and a pending WL decision. However, the stock may offer a favorable risk-reward opportunity in the long term, once NPS momentum improves and there is progress on the MINT regulatory submission.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.